Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis

S Husain, J Allotey, Z Drymoussi, M Wilks, B M Fernandez-Felix, A Whiley, J Dodds, S Thangaratinam, C McCourt, E M Prosdocimi, W G Wade, B M de Tejada, J Zamora, K Khan, M Millar, S Husain, J Allotey, Z Drymoussi, M Wilks, B M Fernandez-Felix, A Whiley, J Dodds, S Thangaratinam, C McCourt, E M Prosdocimi, W G Wade, B M de Tejada, J Zamora, K Khan, M Millar

Abstract

Objective: To determine the effects on the vaginal microbiota of an oral probiotic preparation administered from early pregnancy.

Design: Randomised, double blind, placebo-controlled trial.

Setting: Four maternity units in the UK.

Population: Women aged 16 years or older recruited at 9-14 weeks' gestation.

Methods: Participants were randomly allocated to receive oral capsules of probiotic containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each at 2.5 × 109 colony-forming units (CFUs) or placebo once daily from recruitment until the end of pregnancy.

Main outcome measure: Rates of bacterial vaginosis (BV, defined as Nugent score ≥7) at 18-20 weeks' gestation compared by logistic regression adjusted for possible confounders.

Results: The primary analysis included 78% (238/304) of participants who initially consented (probiotic group 123, placebo group 115). Of these participants, 95% (227/238) reported an intake of 93% or more of the required number of capsules. The rates of BV did not differ between groups at 18-20 weeks' gestation (15% (19/123) in the probiotic group vs. 9% (10/115) in the placebo group, adjusted odds ratio 1.82, 95% confidence interval 0.64-5.19). There were also no differences between the groups in the proportion of women colonised with the probiotic strains, Escherichia coli, group B streptococci or other vaginal microbiota. There were no differences in the alpha diversity or composition of the bacterial communities between or within the probiotic and placebo groups at 9-14 and 18-20 weeks' gestation.

Conclusions: Oral probiotics taken from early pregnancy did not modify the vaginal microbiota.

Tweetable abstract: The oral probiotic preparation used in this study does not prevent BV in pregnant women.

Trial registration: ClinicalTrials.gov NCT02692820.

Keywords: Lactobacillus reuteri; Lactobacillus rhamnosus; Bacterial vaginosis; probiotic.

© 2019 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

Figures

Figure 1
Figure 1
Flow chart showing numbers of participants at each stage of the trial.
Figure 2
Figure 2
Mean Nugent scores with 95% confidence intervals from 9–14 to 34–36 weeks’ gestation of participants in the trial.
Figure 3
Figure 3
Heat map showing the composition of the vaginal microbiota at baseline and at 18–20 weeks’ in placebo and probiotic groups.

References

    1. DiGiulio DB, Callahan BJ, McMurdie PJ, Costello EK, Lyell DJ, Robaczewska A, et al. Temporal and spatial variation of the human microbiota during pregnancy. Proc Natl Acad Sci U S A 2015;112:11060–5.
    1. Donders GG, Van Calsteren K, Bellen G, Reybrouck R, Van den Bosch T, Riphagen I, et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG 2009;116:1315–24.
    1. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007;21:375–90.
    1. Wilks M, Wiggins R, Whiley A, Hennessy E, Warwick S, Porter H, et al. Identification and H2O2 production of vaginal lactobacilli from pregnant women at high risk of preterm birth and relation with outcome. J Clin Microbiol 2004;42:713–7.
    1. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2013;(1):CD000262.
    1. BASHH (2012) UK national guideline for the management of bacterial vaginosis 2012. British Association for Sexual Health and HIV. .
    1. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy 2015;35:1052–62.
    1. Stokholm J, Schjorring S, Eskildsen CE, Pedersen L, Bischoff AL, Folsgaard N, et al. Antibiotic use during pregnancy alters the commensal vaginal microbiota. Clin Microbiol Infect 2014;20:629–35.
    1. Kuperman AA, Koren O. Antibiotic use during pregnancy: how bad is it? BMC Med 2016;14:91.
    1. FAO/WHO Expert Consultation Group . Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Geneva: WHO; 2007.
    1. Yeganegi M, Watson CS, Martins A, Kim SO, Reid G, Challis JR, et al. Effect of Lactobacillus rhamnosus GR‐1 supernatant and fetal sex on lipopolysaccharide‐induced cytokine and prostaglandin‐regulating enzymes in human placental trophoblast cells: implications for treatment of bacterial vaginosis and prevention of preterm labor. Am J Obstet Gynecol 2009;200:532.e1–8.
    1. Piewngam P, Zheng Y, Nguyen TH, Dickey SW, Joo HS, Villaruz AE, et al. Pathogen elimination by probiotic Bacillus via signalling interference. Nature 2018;562:532–7.
    1. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, Wolner‐Hanssen P, et al. Hydrogen peroxide‐producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996;174:1058–63.
    1. Krauss‐Silva L, Moreira ME, Alves MB, Braga A, Camacho KG, Batista MR, et al. A randomised controlled trial of probiotics for the prevention of spontaneous preterm delivery associated with bacterial vaginosis: preliminary results. Trials 2011;12:239.
    1. Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic‐supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double‐blind, placebo‐controlled study. Br J Nutr 2010;103:1792–9.
    1. Tachedjian G, O'Hanlon DE, Ravel J. The implausible ‘in vivo’ role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. Microbiome 2018;6:29.
    1. Othman M, Neilson JP, Alfirevic Z. Probiotics for preventing preterm labour. Cochrane Database Syst Rev 2007;(1):CD005941.
    1. Petricevic L, Unger FM, Viernstein H, Kiss H. Randomized, double‐blind, placebo‐controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2008;141:54–7.
    1. Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001;30:49–52.
    1. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, et al. Oral use of Lactobacillus rhamnosus GR‐1 and L. fermentum RC‐14 significantly alters vaginal flora: randomized, placebo‐controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003;35:131–4.
    1. Vujic G, Jajac Knez A, Despot Stefanovic V, Kuzmic VV. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double‐blind, randomized, placebo‐controlled study. Eur J Obstet Gynecol Reprod Biol 2013;168:75–9.
    1. Gy‐Na‐Tren ‐ Homeopathic Treatment for Feminine Health. []. Accessed 5 December 2017.
    1. OptiBac ‘For women’. []. Accessed 5 December 2017.
    1. Schulz KF, Altman DG, Moher D, Group C . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
    1. Kaunitz AM, Portman D, Westhoff CL, Archer DF, Mishell DR Jr, Foegh M. Self‐reported and verified compliance in a phase 3 clinical trial of a novel low‐dose contraceptive patch and pill. Contraception 2015;91:204–10.
    1. Kane SP. Sample Size Calculator. ClinCalc. []. Accessed 1 July 2017.
    1. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297–301.
    1. Husain SM, Wilks M, Mupita M, Reddy SP, Hennessy EM, Macfarlane AJ, et al. Diversity and stability of cultured vaginal lactobacilli in pregnant women from a multi‐ethnic urban UK population. J Appl Microbiol 2014;117:258–65.
    1. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high‐resolution sample inference from Illumina amplicon data. Nat Methods 2016;13:581–3.
    1. Kahan BC, Jairath V, Dore CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials 2014;15:139.
    1. StataCorp . 2014. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.
    1. Rayment J, Lanlehin R, McCourt C, Husain SM. Involving seldom‐heard groups in a PPI process to inform the design of a proposed trial on the use of probiotics to prevent preterm birth: a case study. Res Involv Engagem 2017;3:11.
    1. van‘t Hooft J, Duffy JM, Daly M, Williamson PR, Meher S, Thom E, et al. A core outcome set for evaluation of interventions to prevent preterm birth. Obstet Gynecol 2016;127:49–58.
    1. Moss N, Daru J, Lanz D, Thangaratinam S, Khan KS. Involving pregnant women, mothers and members of the public to improve the quality of women's health research. BJOG 2017;124:362–5.
    1. Office for National Statistics [GB]. Birth characteristics in England and Wales . 2015. Annual live births by sex, ethnicity and month, maternities by place of birth and with multiple births, and stillbirths by age of parents and calendar quarter. []. Accessed 31 January 2019.
    1. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013;138:1–11.
    1. Mullineaux‐Sanders C, Suez J, Elinav E, Frankel G. Sieving through gut models of colonization resistance. Nat Microbiol 2018;3:132–40.
    1. Nishijima K, Shukunami K‐i, Kotsuji F. Probiotics affects vaginal flora in pregnant women, suggesting the possibility of preventing preterm labor. J Clin Gastroenterol 2005;39:447–8.
    1. Petersen I, Gilbert R, Evans S, Ridolfi A, Nazareth I. Oral antibiotic prescribing during pregnancy in primary care: UK population‐based study. J Antimicrob Chemother 2010;65:2238–46.
    1. Fiscella K. The risk of low birth weight associated with vaginal douching. Obstet Gynecol 1998;92:913–7.
    1. Salisbury C, O'Cathain A, Thomas C, Edwards L, Gaunt D, Dixon P, et al. Telehealth for patients at high risk of cardiovascular disease: pragmatic randomised controlled trial. BMJ 2016;353:i2647.
    1. Palmer S, Pudwell J, Smith GN, Reid RL. Optimizing participation of pregnant women in clinical trials: factors influencing decisions about participation in medication and vaccine trials. J Obstet Gynaecol Can 2016;38:945–54.
    1. Tachedjian G, Aldunate M, Bradshaw CS, Cone RA. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol 2017;168:782–92.
    1. Gille C, Boer B, Marschal M, Urschitz MS, Heinecke V, Hund V, et al. Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial. Am J Obstet Gynecol 2016;215:608 e1–e7.
    1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A‐B, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162–72.
    1. Chang HH, Larson J, Blencowe H, Spong CY, Howson CP, Cairns‐Smith S, et al. Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index. Lancet 2013;381:223–34.
    1. Yang P, Chen YH, Yen CF, Chen HL. Psychiatric diagnoses, emotional‐behavioral symptoms and functional outcomes in adolescents born preterm with very low birth weights. Child Psychiatry Hum Dev 2015;46:358–66.
    1. Myhre R, Brantsaeter AL, Myking S, Gjessing HK, Sengpiel V, Meltzer HM, et al. Intake of probiotic food and risk of spontaneous preterm delivery. Am J Clin Nutr 2011;93:151–7.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅